Retatrutide RecompDual-Axis Protocol

Who This Is For

Experienced users who are committed to training and want:

• Maximum fat loss while preserving or building lean mass
• Targeted visceral fat reduction
• Deep recomposition: looking bigger while weighing less
• Sustained energy and recovery despite aggressive deficit

This is not a first-line protocol. It assumes you're training 4+ days per week, eating adequate protein, and comfortable with multi-compound stacks.

The Problem with GLP-1 Monotherapy

GLP-1 agonists work—the appetite suppression is real, the deficit follows. But something is wrong with the outcomes.

People are lighter but weaker. Thinner but exhausted. The scale moves, but energy doesn't follow. In clinical trials, lean tissue accounts for a significant portion of weight lost: approximately 40% with semaglutide (STEP-1 DXA, 68 weeks) and 25% with tirzepatide (SURMOUNT-1 DXA, 72 weeks). For someone losing fifty pounds on semaglutide without countermeasures, that's roughly twenty pounds of muscle gone.

GLP-1 drugs create deficits by suppressing appetite. But a deficit is pressure, not direction. Without signals telling the body what to burn, it burns both fat and muscle.

Weight loss requires two axes working together:

• Central axis — appetite, intake behavior, the decision to eat. GLP-1s address this effectively.
• Peripheral axis — oxidation machinery, mitochondrial capacity, the ability to burn what's been mobilized. GLP-1s ignore this axis—semaglutide and tirzepatide actively impair it by suppressing glucagon.

This is why GLP-1 monotherapy produces weight loss but not recomposition.

Why Retatrutide Is Different

Retatrutide activates three receptors: GLP-1, GIP, and glucagon. The first two provide appetite suppression and glycemic smoothing. The third—glucagon—is what separates retatrutide from its predecessors.

Glucagon receptor activation preserves the liver's fat oxidation. Resting energy expenditure rises rather than falls. Fat is mobilized and burned, not just stored less.

At high doses (8–12 mg), retatrutide behaves as a bariatric drug. But this protocol uses retatrutide differently: as a low-dose metabolic stabilizer (1–4 mg), creating the foundation for directed fat loss while other compounds build oxidation capacity.

The Fat-Burning Chain

Fat burning is not one step. It is a chain, and every link must be present:

1. Retatrutide → releases fat from storage (mobilization)
2. L-Carnitine → transports fat into mitochondria (logistics)
3. MOTS-c → programs mitochondria to prefer fat (the switch)
4. NAD+ → provides capacity to complete combustion (execution)

Skip any link and the chain weakens.

Retatrutide Mobilizes Fat

The glucagon arm signals adipose tissue to release fatty acids and primes the liver for oxidation. Fat leaves storage and enters the bloodstream. But fat circulating in blood is not fat being burned.

L-Carnitine Transports Fat

Long-chain fatty acids cannot cross the inner mitochondrial membrane on their own. They require the carnitine shuttle. Without adequate carnitine, fatty acids accumulate outside the furnace, unavailable for burning.

MOTS-c Programs Mitochondria

Here's what most approaches miss: fat sitting inside mitochondria is not the same as fat being oxidized.

Mitochondria can burn either glucose or fat. In metabolically inflexible individuals, the system is biased toward glucose. Fat may be present, transported, available, but the machinery isn't set up to prefer it.

MOTS-c is a mitochondrial-derived peptide that activates AMPK, the energy sensor that detects active fuel burning. AMPK triggers pathways that shift cellular preference toward fat oxidation. The mitochondria stop waiting for glucose and start burning what's available.

This is not stimulation. It is reprogramming.

NAD+ Completes Combustion

Once mitochondria are programmed to prefer fat, they need cofactor capacity to complete β-oxidation. NAD+ is required at every step. Without adequate NAD+ pools, the chain stalls at the final step—fat is mobilized, transported, programmed for burning, but cannot complete the process.

The subjective experience is fatigue, brain fog, and the sense of being "wired but underpowered."

The Anabolic Layer: Tesamorelin

The first four layers create a deficit and route it toward fat. But they do not actively protect lean tissue. Under strong catabolic pressure, muscle can still be sacrificed.

Tesamorelin adds the anabolic counterweight. It's a GHRH analog that restores pulsatile growth hormone secretion rather than supplying exogenous GH. The distinction matters: tesamorelin preserves the body's natural rhythm rather than flattening it.

In clinical trials, tesamorelin produces selective effects:

• Visceral adipose tissue decreases
• Lean mass is preserved or modestly increased
• Hepatic fat fraction drops

The visceral fat reduction creates a feedback loop. Visceral fat secretes inflammatory cytokines, worsens insulin resistance, and impairs fuel-routing. As visceral fat decreases, insulin sensitivity improves, and the fat-as-fuel bias becomes easier to maintain.

Circadian alignment matters: GH secretion is naturally nocturnal. Tesamorelin amplifies this pattern, supporting a clean division—daytime for AMPK-dominant oxidation, nighttime for mTOR-dominant repair.

Dosing

Use the reconstitution calculator to determine exact injection volumes for each compound.

Weekly Schedule (Example)

MOTS-c Cycling

MOTS-c activates AMPK–PGC1α transcription for ~72 hours. An activated pathway does not need re-activation. Little benefit is gained by increasing frequency.

Lifestyle Foundation

Timeline: What to Expect

When Progress Stalls

Managing Side Effects

Monitoring

IGF-1 guidance: Target physiologic elevation. If IGF-1 exceeds 350–400 ng/mL, reduce Tesamorelin dose.

What Comes Next

Maintenance:

• Reduce retatrutide to 2–3 mg/week
• Tesamorelin to 1 mg nightly for sleep/connective tissue support
• NAD+ at 100–150 mg on training days
• L-Carnitine pre-training as needed

Lean-gain phase:

• Discontinue retatrutide
• Maintain Tesamorelin
• Increase calories to slight surplus
• Continue NAD+ and L-Carnitine
• Goal: slow, clean accrual of lean mass

Contraindications

• Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
• Active malignancy (GH/IGF-1 axis; MOTS-c)
• Proliferative diabetic retinopathy
• Pregnancy or breastfeeding
• Uncontrolled diabetes (requires close monitoring)

FAQ

Why use low-dose retatrutide instead of full dose?
Full-dose retatrutide (8–12 mg) is a powerful deficit creator but can overwhelm fat oxidation capacity. Low-dose (1–4 mg) mobilizes fat without collapsing metabolic rate, while other compounds build the machinery to burn what's released.

Can I skip the anabolic layer (Tesamorelin)?
You can, but expect more lean mass loss. Tesamorelin provides the growth hormone signal that protects muscle during aggressive deficits and improves visceral fat targeting.

How do I know if the protocol is working?
Track waist circumference and strength performance, not just scale weight. Recomposition often shows as stable or dropping weight with maintained or increased strength and smaller waist.

What happens after 12 weeks?
Transition to maintenance (lower doses) or a lean-gain phase (discontinue retatrutide, maintain tesamorelin, slight caloric surplus). The metabolic improvements persist if habits are maintained.

Related Topics

• GLP-1 Compounds Tool — interactive comparison with trial data on weight loss and composition
• Retatrutide + NAD Beginner Protocol — simpler starting point
• Retatrutide Guide — mechanism, trials, and safety data
• Tesamorelin Guide — the anabolic layer explained
• AOD-9604 Guide — optional lipolytic support for stubborn areas
• NAD+ Guide — cofactor support for fat oxidation
• MOTS-c Guide — mitochondrial programming peptide
• MITT-Stack White Paper — mitochondrial peptide deep-dive
• GLP-1 Muscle Preservation — body composition strategies
• GLP-1 Comparison — how agents compare

References

• Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023. https://doi.org/10.1056/NEJMoa2301972
• Stanley TL, et al. Effects of Tesamorelin on Non-Alcoholic Fatty Liver Disease. Lancet HIV 2019. https://doi.org/10.1016/S2352-3018(19)30338-8
• Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis. Cell Metabolism 2015. https://doi.org/10.1016/j.cmet.2015.02.009
• Stephens FB, et al. Skeletal Muscle Carnitine Loading Increases Energy Expenditure. Journal of Physiology 2013. https://doi.org/10.1113/jphysiol.2013.255364
• Yoshino J, et al. NAD+ Intermediates: The Biology and Therapeutic Potential. Cell Metabolism 2021. https://doi.org/10.1016/j.cmet.2020.11.007

Educational content only. Some compounds discussed are FDA-approved medications; others are research peptides without FDA approval — not due to safety concerns, but because unpatentable compounds cannot justify the required trial investment. Work with a qualified healthcare provider before using any protocol.